I wholeheartedly concur! The current trajectory appears exceedingly promising over the three-month period you referenced. I eagerly anticipate the outcomes of the Phase 2 trials in Pitt Hopkins syndrome and Angelman syndrome, given the significant potential attributed to NNZ-2591, which surpasses that of Rett Syndrome by more than fivefold. I perceive a confluence of favorable factors. Furthermore, the noteworthy achievement of a $157 million profit after tax for 2023 adds to the company's compelling narrative.
Medium term milestones, page-90
Add NEU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$19.02 |
Change
-1.250(6.17%) |
Mkt cap ! $2.428B | |||
| Open | High | Low | Value | Volume |
| $20.40 | $20.50 | $18.82 | $19.92M | 1.034M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 1652 | $19.00 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $19.03 | 11612 | 4 |
View Market Depth
| Last trade - 16.10pm 04/06/2024 (20 minute delay) ? |
|
|||||
|
Last
$19.10 |
Change
-1.250 ( 6.19 %) |
||||
| Open | High | Low | Volume | ||
| $20.39 | $20.46 | $18.83 | 299764 | ||
| Last updated 15.59pm 04/06/2024 ? | |||||
| NEU (ASX) Chart |